| Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers |
Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 2027, providing financial stability to reach key milestones and possibly raise funds from a stronger position. Other pipeline candidates, CTX-471 and CTX-8371, have upcoming trials and readouts in 2025, adding potential value to CMPX's portfolio. |
seekingalpha.com |
2025-05-13 01:51:07 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update |
Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. |
globenewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Participate in Upcoming May Investor Events |
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences Conference Location: New York, NY Date: Thursday, May 8, 2025 Time: 1:30 PM ET Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C. |
globenewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting |
CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models. |
globenewswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| 2 Penny stocks to buy in May 2025 |
Summary ⚈ Market conditions in May create opportunities for penny stock investors.⚈ Compass Therapeutics and Blade Air Mobility are highlighted for strong growth prospects. |
finbold.com |
2025-04-27 13:17:39 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer |
BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center. |
globenewswire.com |
2025-04-21 12:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum |
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. |
globenewswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer |
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review. |
globenewswire.com |
2025-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer |
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC). |
globenewswire.com |
2025-03-31 20:05:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update |
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock? |
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-10 15:01:24 |
Czytaj oryginał (ang.) |
| Top 3 High-Momentum Companies Analysts Are Still Bullish On |
The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they decline. As a result, momentum is typically favored in short-term and active trading strategies rather than long-term investing. |
marketbeat.com |
2025-02-04 09:03:33 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why |
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company. |
zacks.com |
2025-01-31 14:20:16 |
Czytaj oryginał (ang.) |
| Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year? |
Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year. |
zacks.com |
2024-12-10 12:41:36 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer |
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. |
globenewswire.com |
2024-12-10 10:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer |
Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with $36.8 million in cash and $98.6 million in marketable securities, ensuring a runway through 2025 without major cash concerns. Risks include the non-standard comparator in the pivotal trial and the historically low success rate of novel anti-angiogenic therapies in solid tumors. |
seekingalpha.com |
2024-12-09 14:54:36 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference |
BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024. |
globenewswire.com |
2024-12-02 10:00:00 |
Czytaj oryginał (ang.) |
| Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX) |
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-11-21 12:35:21 |
Czytaj oryginał (ang.) |
| What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock |
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-11-15 15:00:23 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Participate in Upcoming Investor Events |
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024. |
globenewswire.com |
2024-11-13 10:30:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update |
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter 2024 financial results and provided a business update. |
globenewswire.com |
2024-11-12 10:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting |
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody” at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX. |
globenewswire.com |
2024-11-08 12:05:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting |
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. |
globenewswire.com |
2024-10-04 14:31:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Participate in Upcoming Investor Events |
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2024. |
globenewswire.com |
2024-09-03 12:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference |
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET. |
globenewswire.com |
2024-08-07 12:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why |
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-07-10 17:00:38 |
Czytaj oryginał (ang.) |
| Compass Therapeutics: Pointing Right At Some Tough Cancers |
Compass Therapeutics is an oncology-focused biotech developing novel immunotherapies for solid tumors, with a focus on gastrointestinal cancers. Their most advanced candidate, CTX-009, targets DLL4 and VEGF in biliary tract cancer, showing promising early response rates. Despite financial stability and potential game-changing catalysts, risks include toxicity concerns and comparator arm issues in their phase 3 trial. |
seekingalpha.com |
2024-06-20 07:14:50 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference |
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024. |
globenewswire.com |
2024-05-30 12:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Announces CEO Transition |
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. |
globenewswire.com |
2024-05-28 20:10:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 |
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced an upcoming poster presentation of its novel anti-CD137 agonist antibody, CTX-471, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies. |
globenewswire.com |
2024-05-23 21:05:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference |
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024. |
globenewswire.com |
2024-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update |
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2024 financial results and provided a business update. |
globenewswire.com |
2024-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference |
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company's bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024. |
globenewswire.com |
2024-04-12 12:00:00 |
Czytaj oryginał (ang.) |